0.628
Jupiter Neurosciences Inc (JUNS) 最新ニュース
Jupiter Neurosciences Inc. (JUNS) reports earnings - Quartz
Jupiter Neurosciences faces NASDAQ delisting over share price By Investing.com - Investing.com South Africa
Jupiter Neurosciences faces NASDAQ delisting over share price - Investing.com
Jupiter Neurosciences, Catalent Partner to Produce JOTROL Softgels for Upcoming Trial - Contract Pharma
Alliance Entertainment and Jupiter Neurosciences Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Bluefield Daily Telegraph
Jupiter Neurosciences and Aquanova AG Announce Strategic - GlobeNewswire
Jupiter Neurosciences, Aquanova announce strategic collaboration - TipRanks
Jupiter Neurosciences partners with Aquanova on health products By Investing.com - Investing.com South Africa
Jupiter Neurosciences And Aquanova AG Announce Strategic Collaboration To Develop Longevity And Healthspan Products - Marketscreener.com
Jupiter Neurosciences partners with Aquanova on health products - Investing.com
Can Jupiter Neurosciences Capture The $44B Longevity Market With Its New Aquanova Partnership? - StockTitan
Jupiter Neurosciences Inc (JUNS) Shares Decline Despite Market Challenges - The News Heater
Jupiter Neurosciences partners with Catalent for Parkinson’s trial By Investing.com - Investing.com Nigeria
Three technology stocks with differentiated value propositions | 2025-02-07 | Investing News - Stockhouse Publishing
Jupiter Neurosciences partners with Catalent for Parkinson's trial - MSN
Jupiter Neurosciences Addresses Market Volatility as it - GlobeNewswire
Jupiter Neurosciences says volatility ‘appears to be driven by misconceptions’ - TipRanks
Jupiter Neurosciences Addresses Market Volatility as it Remains Focused on Advancing Clinical and Commercial Milestones - TradingView
Inside Jupiter's $50B Market Strategy: NIH Funding Secured, Phase 2 Trials Set for Revolutionary CNS Treatment - Stock Titan
Jupiter Neurosciences Partners With Catalent For Parkinson's JOTROL Trial Production - Nasdaq
Jupiter Neurosciences Signs Manufacturing Deal With Catalent Pharma for Jotrol Softgel Capsules - Marketscreener.com
Jupiter Neurosciences Partners with Catalent to Produce JOTROL Softgels for Upcoming Clinical Trial - Contract Pharma
Jupiter Neurosciences partners with Catalent for Parkinson's trial By Investing.com - Investing.com South Africa
Clinical Trials News Live Feed - StockTitan
Jupiter Neurosciences Announces JOTROL Manufacturing - GlobeNewswire
Jupiter Neurosciences Announces JOTROL Manufacturing Agreement with Catalent to Support Phase 2a Parkinson's Trial - The Manila Times
Major Breakthrough: New Parkinson's Drug Manufacturing Deal Could Fast-Track Treatment for 10M Patients - StockTitan
Phase 2a trial of Jotrol as treatment for Parkinson’s planned - Parkinson's News Today
Jupiter Neurosciences partners with Zina for Parkinson's trial - Investing.com India
Jupiter Neurosciences, Zina Biopharmaceuticals Collaborate on Phase 2a Parkinson's Disease Study - Marketscreener.com
Jupiter Neurosciences Partners with Zina Biopharmaceuticals to Advance Phase 2a Parkinson’s Trial - GlobeNewswire
Jupiter Neurosciences partners with Zina for Parkinson's trial By Investing.com - Investing.com South Africa
Jupiter Neurosciences Partners With Zina Biopharmaceuticals To Launch Phase 2a Parkinson's Trial - Nasdaq
Wall Street Set to Open Slightly Lower Friday as Investors Await PMI, Housing Figures - TradingView
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
United States shares higher at close of trade; Dow Jones Industrial Average up 0.93% - Investing.com India
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.93% - Investing.com
U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.93% - Investing.com UK
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Stock market news: Chanson International Holdings declined by 83.97% while Dogwood Therapeutics surged by 387.32% during mid day trading - Business Upturn
Stock market today: Icon Energy surged by 222.66% while Jupiter Neurosciences gained over 208.62% in early trading - Business Upturn
US Stocks Mixed; GE Aerospace Posts Upbeat Earnings - Benzinga
Modest Final Quarter Completes Shaky Biotech IPO Comeback For 2024 - News & Insights
Stock market news: Star Fashion Culture Holdings -78.42%, Lisata Therapeutics -33.08% among biggest losers in early trading - Business Upturn
Stock market today: Star Fashion Culture Holdings -79.05%, Lisata Therapeutics -23.34% among biggest losers in early trading - Business Upturn
Twin Vee PowerCats Co. New 5-Axis CNC Router to Harness Advanced Robotics in Production Process - The Globe and Mail
Biopharma IPOs rebound slightly, as class of 2024 lags with a 29% average decline - BioWorld Online
Jupiter Neurosciences refocuses on NLRP3 inflammasome By Investing.com - Investing.com South Africa
Jupiter Neurosciences refocuses on NLRP3 inflammasome - Investing.com India
Jupiter Neurosciences Announces Strategic Focus on NLRP3 Pathway in Future JOTROL™ Trials - GlobeNewswire
Jupiter Neurosciences announces focus on NLRP3 pathway in JOTROL trials - TipRanks
Jupiter Neurosciences Targets NLRP3 Inflammasome With JOTROL Platform for Alzheimer's Treatment - StockTitan
Pre-market Movers: ONCO, EYEN, SGMO, VSTM... - RTTNews
December's $4.69B in biopharma financings caps a $102.15B year - BioWorld Online
大文字化:
|
ボリューム (24 時間):